ACE-inhibition is Superior to Endothelin A Receptor Blockade in Preventing Abnormal Capillary Supply and Fibrosis of the Heart in Experimental Diabetes

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2004 Jan 17

PMID 14727024

Citations 17

Authors

M-L Gross

N Heiss

M Weckbach

A Hansen

A El-Shakmak

A Szabo

K Munter

E Ritz

K Amann

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: There is little information whether cardiac capillary supply is deranged in diabetes. Hyperglycaemia is a potent stimulus for endothelin-1 (ET-1) production. We therefore hypothesised that increased ET-1 production in Streptozotocin-induced Type 1 diabetes causes abnormalities of cardiac capillaries and the aorta. To this end we compared the effects of an ET receptor A blocker (ETA-RB) with that of an ACE-inhibitor (ACE-i) or their combination in rats with Streptozotocin (STZ) diabetes.

Methods: Sprague Dawley rats were injected with 65 mg STZ i.v. and subsequently developed diabetes. Rats were left untreated or received daily either the ACE-i Trandolapril, the ETA-RB Darusentan or a combination of both. After 6 months the experiment was terminated and the heart and the aorta were investigated using quantitative morphological techniques.

Results: ACE-i but not ETA-RB lowered blood pressure in STZ Type 1 diabetic rats. Capillary length density was lower in untreated STZ diabetic rats (2932+/-128 mm/mm3) compared to non-diabetic control rats (3410+/-252 mm/mm3). Treatment with ACE-i (3568+/-431 mm/mm3), but not with ETA-RB (2893+/-192 mm/mm3), prevented the decrease in capillary supply. Volume density of the myocardial interstitium was higher in untreated STZ diabetic rats (0.86+/-0.04%) compared to non-diabetic control rats (0.36+/-0.06%). In all three intervention groups the values were lower (ACE-i: 0.53+/-0.05%, ETA-RB: 0.7+/-0.08% and combination: 0.69+/-0.1).

Conclusion/interpretation: Our study identifies a capillary defect of the heart in STZ diabetes, i.e. decreased capillary supply. This abnormality was reversed by ACE-i, but not by ETA-R blockade. A similar trend, although not complete normalisation, was seen in cardiac fibrosis.

Citing Articles

The Potential of Albuminuria as a Biomarker of Diabetic Complications.

Raja P, Maxwell A, Brazil D Cardiovasc Drugs Ther. 2020; 35(3):455-466.

PMID: 32681438 PMC: 8105227. DOI: 10.1007/s10557-020-07035-4.

Overexpression of hexokinase 2 reduces mitochondrial calcium overload in coronary endothelial cells of type 2 diabetic mice.

Pan M, Han Y, Basu A, Dai A, Si R, Willson C Am J Physiol Cell Physiol. 2018; 314(6):C732-C740.

PMID: 29513568 PMC: 6334999. DOI: 10.1152/ajpcell.00350.2017.

Obesity-induced vascular inflammation involves elevated arginase activity.

Yao L, Bhatta A, Xu Z, Chen J, Toque H, Chen Y Am J Physiol Regul Integr Comp Physiol. 2017; 313(5):R560-R571.

PMID: 28835451 PMC: 5792147. DOI: 10.1152/ajpregu.00529.2016.

Endothelin and the glomerulus in chronic kidney disease.

Barton M, Sorokin A Semin Nephrol. 2015; 35(2):156-67.

PMID: 25966347 PMC: 4731878. DOI: 10.1016/j.semnephrol.2015.02.005.

VDAC: old protein with new roles in diabetes.

Sasaki K, Donthamsetty R, Heldak M, Cho Y, Scott B, Makino A Am J Physiol Cell Physiol. 2012; 303(10):C1055-60.

PMID: 22972802 PMC: 3492836. DOI: 10.1152/ajpcell.00087.2012.

References

Takahashi K, Ghatei M, Lam H, OHalloran D, Bloom S . Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia. 1990; 33(5):306-10. DOI: 10.1007/BF00403325. View

Ayaz M, Can B, Ozdemir S, Turan B . Protective effect of selenium treatment on diabetes-induced myocardial structural alterations. Biol Trace Elem Res. 2002; 89(3):215-26. DOI: 10.1385/bter:89:3:215. View

Chua B, Chua C, Diglio C, Siu B . Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta. 1993; 1178(2):201-6. DOI: 10.1016/0167-4889(93)90010-m. View

Gurbanov K, Rubinstein I, Hoffman A, Abassi Z, Better O, Winaver J . Bosentan improves renal regional blood flow in rats with experimental congestive heart failure. Eur J Pharmacol. 1996; 310(2-3):193-6. DOI: 10.1016/0014-2999(96)00494-3. View

Zoja C, Orisio S, Perico N, Benigni A, Morigi M, Benatti L . Constitutive expression of endothelin gene in cultured human mesangial cells and its modulation by transforming growth factor-beta, thrombin, and a thromboxane A2 analogue. Lab Invest. 1991; 64(1):16-20. View

Riva E, Andreoni G, Bianchi R, Latini R, Luvara G, Jeremic G . Changes in diastolic function and collagen content in normotensive and hypertensive rats with long-term streptozotocin-induced diabetes. Pharmacol Res. 1998; 37(3):233-40. DOI: 10.1006/phrs.1998.0290. View

Buzello M, Boehm C, Orth S, Fischer B, Ehmke H, Ritz E . Myocyte loss in early left ventricular hypertrophy of experimental renovascular hypertension. Virchows Arch. 2003; 442(4):364-71. DOI: 10.1007/s00428-003-0775-5. View

Rodriguez-Porcel M, Lerman A, Ritman E, Wilson S, Best P, Lerman L . Altered myocardial microvascular 3D architecture in experimental hypercholesterolemia. Circulation. 2000; 102(17):2028-30. DOI: 10.1161/01.cir.102.17.2028. View

HAYNES W, Ferro C, Webb D . Bosentan in essential hypertension. N Engl J Med. 1998; 339(5):346; author reply 347. DOI: 10.1056/NEJM199807303390513. View

10.

WOODS L, Mizelle H, Hall J . Control of renal hemodynamics in hyperglycemia: possible role of tubuloglomerular feedback. Am J Physiol. 1987; 252(1 Pt 2):F65-73. DOI: 10.1152/ajprenal.1987.252.1.F65. View

11.

Weber K, Brilla C . Structural basis for pathologic left ventricular hypertrophy. Clin Cardiol. 1993; 16(5 Suppl 2):II10-4. DOI: 10.1002/clc.4960161404. View

12.

Hong S, Isono M, Chen S, Iglesias-de la Cruz M, Han D, Ziyadeh F . Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol. 2001; 158(5):1653-63. PMC: 1891936. DOI: 10.1016/s0002-9440(10)64121-1. View

13.

HAYNES W, Webb D . Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens. 1998; 16(8):1081-98. DOI: 10.1097/00004872-199816080-00001. View

14.

Weber K, Brilla C, Campbell S, Guarda E, Zhou G, Sriram K . Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol. 1993; 88 Suppl 1:107-24. DOI: 10.1007/978-3-642-72497-8_8. View

15.

Suzuki T, Kumazaki T, Mitsui Y . Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun. 1993; 191(3):823-30. DOI: 10.1006/bbrc.1993.1291. View

16.

Kirchengast M, Munter K . Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med. 1999; 221(4):312-25. DOI: 10.1046/j.1525-1373.1999.d01-88.x. View

17.

Oie E, Clausen O, Yndestad A, Grogaard H, Attramadal H, OIje E . Endothelin receptor antagonism attenuates cardiomyocyte apoptosis after induction of ischemia in rats. Scand Cardiovasc J. 2002; 36(2):108-16. DOI: 10.1080/140174302753675401. View

18.

Cavasin M, Carretero O, Yang F, Oja-Tebbe N, Peng H, Yang X . Long-term effects of selective and nonselective endothelin receptor antagonists in mice with heart failure. J Card Fail. 2002; 8(4):254-61. DOI: 10.1054/jcaf.2002.0804254. View

19.

Fiordaliso F, Li B, Latini R, SONNENBLICK E, Anversa P, Leri A . Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II- dependent. Lab Invest. 2000; 80(4):513-27. DOI: 10.1038/labinvest.3780057. View

20.

Marin-Garcia J, Goldenthal M, Moe G . Selective endothelin receptor blockade reverses mitochondrial dysfunction in canine heart failure. J Card Fail. 2002; 8(5):326-32. DOI: 10.1054/jcaf.2002.127770. View